Insider track record
OtherNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the full record of transactions filed by Doyle Mittie. Director active across 1 company, notably Avalo Therapeutics, Inc.. Cumulatively, 21 filings have been recorded. Breakdown: 0 buy · 8 sells. Total volume traded: €127k. History available since 10 December 2025. The latest transaction was disclosed on 17 August 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Doyle Mittie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
1,000 shares@ US$12.65Common StockSEC:0001918845-26-000029:0
1,000 shares@ US$20.00Common StockSEC:0001918845-26-000029:1
679 shares@ US$8.040.0005% mcap1.2% of flowCommon StockSEC:0001918845-26-000026:0
679 shares@ US$20.000.0013% mcap3.0% of flowCommon StockSEC:0001918845-26-000026:1
1,000 shares@ US$12.650.0012% mcap2.9% of flowCommon StockSEC:0001918845-26-000024:0
1,000 shares@ US$20.000.0019% mcap4.6% of flowCommon StockSEC:0001918845-26-000024:1
2,875 sharesCommon StockSEC:0001918845-26-000022:0
1,779 sharesCommon StockSEC:0001918845-26-000022:1
4,654 sharesCommon StockSEC:0001918845-26-000022:2
1,450 sharesCommon StockSEC:0001918845-26-000020:0
1,450 sharesCommon StockSEC:0001918845-26-000020:1
1,084 sharesCommon StockSEC:0001918845-26-000018:0
679 shares@ US$8.040.0014% mcap33.4% of flowCommon StockSEC:0001918845-26-000016:0
679 shares@ US$16.000.0028% mcap66.6% of flowCommon StockSEC:0001918845-26-000016:1
43,500 shares0Common StockSEC:0001918845-26-000014:0
3,970 shares@ US$18.012251.8% of flowCommon StockSEC:0001918845-26-000008:1
3,970 shares@ US$12.6536.4% of flowCommon StockSEC:0001918845-26-000008:0
679 shares@ US$8.043.5% of flowCommon StockSEC:0001918845-26-000006:0
679 shares@ US$16.007.0% of flowCommon StockSEC:0001918845-26-000006:1
19,500 shares@ US$12.6561.8% of flowCommon StockSEC:0001918845-26-000004:0
1,013 shares@ US$4.101.0% of flowCommon StockSEC:0001470831-25-000412:0
About Doyle Mittie
Doyle Mittie is Chief Medical Officer at Avalo Therapeutics, Inc. This declarant has filed 17 filings in total. In the sampled recent filings, between 2025-12-12 and 2026-07-29, the sell volume is EUR 98216 and the modal transaction nature is Levée d'options.